ALAMEDA, Calif. and TAIPEI, Aug. 08, 2023 - - Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced the Emerging Stock Listing on the Taipei Exchange and the commencement of its first day of trading under the ticker symbol “6976.”
Taishin Securities Co.,Ltd, Yuanta Securities Co., Ltd, and Mega Securities Co., Ltd acted as book-running manager for the offering.
“Our listing on the Taipei Exchange (TPEx: 6976) is a testament to the unwavering support of our investors, dedicated team members, and all stakeholders who have contributed to this remarkable achievement,” said Sonny Hsiao, Ph.D., chief executive officer of Acepodia. “With our commitment to scientific excellence and a patient-centric approach, we eagerly look forward to the future as we commence trading on the exchange, embarking on a new chapter of growth and progress for the company.”
For further details about Acepodia (TPEx: 6976), kindly visit the Market Observation Post System (MOPS) through the publicly available service link created by The Taiwan Stock Exchange Inc. and Taipei Exchange at https://emops.twse.com.tw/server-java/t58query.
https://emops.twse.com.tw/server-java/t58query
About Acepodia
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens. For more information, visit
www.acepodia.com and follow Acepodia on
LinkedIn.
Acepodia Contact:
Acepodia PR Team
pr@acepodiabio.com
